ENITEC archive

European Network of Individual Treatment in Endometrial Cancer


ENITECENITEC is a pan-European academic Network for Gynaecological Oncological Translational Researchers who gather together to share their expertise in uterine cancer research, with a particular focus on integration of molecular studies to improve and individualize patient care.

The ultimate goal of the Network is to improve and individualize treatment of women with uterine cancers by integrating the best science in state of the art for clinical care, and enabling every patient to access benefits from translational research.



Annual Meeting

The 2016 annual meeting will be held on 9th-10th of June in Freiburg, Germany.

Collaborative Studies

The Network will discuss updates about the already ongoing collaborative studies and evaluate the proposal of new projects.

The project entitled “Therapeutic targets in uterine sarcomas: an IHC study”, coordinated by Frederic Amant (KULeuven, BE, ENITEC Co-Chair) and involving from the beginning 13 centres inside ENITEC has been finalized in 2015 and will be published in 2016.

 The validation study aimed to unravel the prognostic  significance  of L1CAM in endometrioid (EEC) and non-endometrioid endometrial cancer (NEEC), coordinated by Johanna Pijnenborg (Tilborg, NL) and Louis Van Der Putten (Nijmegen, NL) and involving several centres inside ENITEC, has been finalized in 2015 and will be published in 2016.
Development of the RUCaRe (Rare Uterine Cancer Registry) initiative.
Clinical Studies
The ENITEC Network provides its members the opportunity to join a TAKEDA sponsored PHASE-II clinical trial commencing in February 2016.
This joint initiative of ENITEC-EUTROC-TAKEDA, involves treatment of women with Advanced, Recurrent, or persistent Endometrial Cancer with MLN0128 (A dual TORC 1/2 inhibitor), MLN0128+MLN117 (a PI3Kα Inhibitor), Weekly Paclitaxel and a combination of weekly Paclitaxel and MLN0128 in 4 patient arms.
260 patients from approximately 60 centres across North America, Europe and Asia Pacific will be randomized into the study.
Tissue material (baseline and follow up biopsies) will be used to generate research material (frozen and fixed tissue) available from the patient arms.
This material will be available to EUTROC-ENITEC investigators from TAKEDA to investigate important translational science questions.

Upcoming events

banner web 194x170

Surgery Course

Ovarian Cancer Surgery Course
Mar 22-24, 2018, Hamburg, Germany

Apply Now!

Read More

ESGO 2018 294X170


ESGO State of the Art 
Oct 4-6, 2018, Lyon, France

Save the Date!

Read More

athens 294x174


Nov 2-5, 2019, Athens, Greece

Save the Date!

Read More